share_log

PaxMedica, Provides Corporate Update After IPO; Appointment Of Stephen D. Sheldon As CFO

PaxMedica, Provides Corporate Update After IPO; Appointment Of Stephen D. Sheldon As CFO

PaxMedica，IPO後提供公司最新消息；任命Stephen D.Sheldon為首席財務官
Benzinga Real-time News ·  2022/09/27 20:12
-PXMD Strengthened Executive Team with Recent Appointment of Stephen D. Sheldon As Chief Financial Officer-
-PXMD最近任命Stephen D.Sheldon為首席財務官，從而加強了高管團隊-
-Second Independent Director, Dr. John F. Coelho, Appointed to Board of Directors in May 2022-
-第二獨立董事，約翰·F·科埃略博士於2022年5月被任命為董事會成員-
TARRYTOWN, NY, Sept. 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica(PXMD.US), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies ("APT") for the treatment of disorders with intractable neurologic symptoms, today provided a corporate update after the Company's initial public offering ("IPO"), which closed on August 26, 2022.
紐約州塔裏敦，9月2022年27日(Global Newswire)--通過NewMediaWire-PaxMedica(PXMD.US)臨牀階段生物製藥公司，專注於開發新型抗嘌呤能藥物療法(APT)，用於治療具有頑固性神經症狀的疾病，今天在公司於2022年8月26日結束的首次公開募股(IPO)後提供了公司最新情況。
Most recently, PaxMedica appointed Stephen D. Sheldon as Chief Financial Officer in July 2022. In May 2022, Dr. John F. Coelho...
最近，PaxMedica於2022年7...
登入免費觀看全文
登入/註冊

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論